Form 4: Precigen Director Boosts Stake with Stock, RSUs, Options

Precigen Director James S. Turley acquired common stock, restricted stock units, and stock options on March 10, 2026, increasing his beneficial ownership.

Summary

• James S. Turley, a Director of Precigen, Inc. (PGEN), reported transactions on March 10, 2026.
• Acquired 17,806 shares of common stock at a price of $3.51 per share, issued in lieu of an annual retainer of $62,500.
• Acquired 35,612 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Precigen common stock.
• The RSUs vest in full on March 10, 2027.
• Acquired 41,073 options to purchase common stock with an exercise price of $3.51 per share.
• The options are exercisable as of March 10, 2026, and expire on March 10, 2036.
• Following these transactions, Mr. Turley beneficially owns 613,578 shares of common stock, 35,612 Restricted Stock Units, and 41,073 options to purchase common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A director increasing their equity stake, even through compensation, generally signals confidence in the company's future performance and aligns management interests with shareholders.

Positives

• A director increasing their beneficial ownership through stock acquisition and equity awards can signal confidence in the company's future prospects.
• Receiving compensation in the form of common stock aligns the director's financial interests with those of shareholders.

Future Outlook

The Restricted Stock Units are scheduled to vest in full on March 10, 2027, and the acquired stock options have an expiration date of March 10, 2036, indicating long-term equity incentives.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a director, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or has strong future prospects. This aligns the director's interests with long-term shareholder value creation.

Comparison to Industry Standards

• While specific comparable companies are not detailed in this Form 4, the practice of compensating directors with equity (stock, RSUs, options) is a common corporate governance standard across many industries, including biotechnology, to align management and director incentives with shareholder returns.
• The exercise price of the options ($3.51) matching the common stock acquisition price suggests a current market valuation for the equity component of compensation.

Related Party Transactions

• The acquisition of 17,806 shares of common stock was in lieu of an annual retainer of $62,500, representing a compensation transaction between the company and a director.

Stakeholder Impact

• Shareholders may view the director's increased equity ownership as a positive indicator of management's commitment and belief in the company's long-term value.
• The compensation structure, including RSUs and options, incentivizes the director to contribute to the company's stock price appreciation.

Next Steps

• Vesting of 35,612 Restricted Stock Units on March 10, 2027.
• Potential exercise of 41,073 stock options by March 10, 2036.

Key Dates

Recommendation

The director's decision to increase their beneficial ownership through both direct stock acquisition (as compensation) and the receipt of significant equity awards (RSUs and options) is a strong signal of confidence in Precigen's future. This insider buying aligns the director's financial interests with shareholders and suggests a belief in the company's long-term value proposition, making it a positive indicator for potential investors.

Keywords

PGEN, Precigen, Insider Transaction, Form 4, Director Stock Acquisition, Restricted Stock Units, Stock Options, Equity Compensation